Gordon Jayson

Gordon Jayson is a Professor of Medical Oncology at the University of Manchester and the Christie Hospital, specializing in anti-angiogenic therapies and ovarian cancer research. He holds a BA, BM,BCh from the University of Oxford, a PhD from the University of Manchester, and clinical qualifications including MRCP and CCST. His research focuses on translating heparan sulfate biology into clinical applications, with a particular emphasis on developing novel anti-angiogenic agents and evaluating biomarkers for treatment response in ovarian cancer.

• Education: Medicine (Oxford), PhD in Heparan Sulfate Biology (Manchester).
• Affiliations: Division of Cancer Sciences, Manchester Cancer Research Centre, NIHR Manchester Biomedical Research Centre.

Research interests include Phase I clinical trials of anti-angiogenic drugs, imaging techniques (DCE-MRI and PET), and the glyco-angiogenesis laboratory program targeting FGF pathways. He leads translational research in Phase III clinical trials evaluating VEGF inhibitors for ovarian cancer. His work also explores biomarkers like Tie2 to predict response to anti-VEGF therapies.

Notable projects include the NIHR Manchester Biomedical Research Centre and collaborations on the VALTIVE1 study. He has contributed to over 247 research outputs, including articles on BRIP1 gene testing, chemotherapy response scores, and olaparib/cediranib combinations. His clinical work focuses on improving outcomes for patients with platinum-resistant ovarian cancer and managing malignant bowel obstruction through innovative therapies.